Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683852 · ClinicalTrials.gov registry record · Phase 3
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT00683852: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00683852 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 225 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00683852, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder
Interventions
- DRUG Placebo
- DRUG Aripiprazole 5mg
- DRUG Aripiprazole 2mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683852
The ClinicalTrials.gov registry entry for NCT00683852 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00683852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683852 about?
NCT00683852 is a clinical study titled "A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy". The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder
What is the current status of trial NCT00683852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2008-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00683852?
The interventions under investigation include: Placebo (DRUG), Aripiprazole 5mg (DRUG), Aripiprazole 2mg (DRUG).
Who is sponsoring clinical trial NCT00683852?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.